Related Experiment Video
Updated: Mar 7, 2026

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer
Tung-Yi Lin1,2, Hsien-Yeh Hsu1,2,3, Wei-Hsuan Sun2
1Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan.
Abstract:
Activating mutation of epidermal growth factor receptor (EGFR) is correlated with malignant lung tumor. In our study, we demonstrated that recombinant LZ-8 (rLZ-8), a medicinal mushroom Ganoderma lucidum protein, induced cell cycle arrest and apoptosis by downregulating the expression of wild-type and mutated EGFR and inhibiting EGFR downstream effectors, AKT and ERK1/2 in lung cancer cells. We showed that rLZ-8 effectively inhibited lung cancer progression and suppressed EGFR expression of lung tumor lesions in mouse model. Functional studies revealed that rLZ-8 reduced the amount of EGFR in cell membranes by altering EGFR localization to enhance the EGF-induced degradation of EGFR. Mechanistically, we demonstrated that rLZ-8 bound to EGFR to induce EGFR autophosphorylation at tyrosine1045 and trigger ubiquitination by inducing the formation of EGFR/Cbl complexes, resulting in the degradation of EGFR; however, Cbl-shRNA abolished rLZ-8-induced EGFR degradation. We provide the first evidence showing that rLZ-8 inhibits growth and induces apoptosis of lung cancer cells by promoting EGFR degradation. The current findings therefore suggest a novel anti-cancer function of rLZ-8 that targeting EGFR overexpression or mutation as well as EGFR-dependent processes in cancer cells.
Insights
Recombinant LZ-8 (rLZ-8), a mushroom protein, halts lung cancer growth by promoting the degradation of epidermal growth factor receptor (EGFR). This novel mechanism inhibits EGFR signaling, offering a potential new cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activating mutations in the epidermal growth factor receptor (EGFR) are linked to lung cancer.
- EGFR signaling pathways are crucial for cancer cell proliferation and survival.
Purpose of the Study:
- To investigate the anti-cancer effects of recombinant LZ-8 (rLZ-8) from Ganoderma lucidum on lung cancer cells.
- To elucidate the mechanism by which rLZ-8 affects EGFR expression and downstream signaling.
Main Methods:
- Cell culture and treatment with rLZ-8.
- Western blotting to assess protein expression (EGFR, AKT, ERK1/2).
- Mouse xenograft models to evaluate tumor growth inhibition.
- Analysis of EGFR localization, degradation, and complex formation with Cbl.
Main Results:
- rLZ-8 induced cell cycle arrest and apoptosis in lung cancer cells.
- rLZ-8 downregulated wild-type and mutated EGFR expression and inhibited AKT/ERK1/2.
- rLZ-8 suppressed tumor growth and EGFR expression in vivo.
- rLZ-8 promoted EGFR degradation by enhancing its ubiquitination and Cbl complex formation.
Conclusions:
- rLZ-8 exhibits anti-cancer properties by promoting EGFR degradation, offering a novel therapeutic strategy.
- Targeting EGFR degradation represents a promising approach for treating lung cancer, particularly those with EGFR mutations or overexpression.
Related Concept Videos
Mitogens and the Cell Cycle
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...